The histone modifier KAT2A presents a selective target in a subset of well-differentiated microsatellite-stable colorectal cancers
V. Kufrin, A. Seiler, S. Brilloff, H. Rothfuss, S. Schuster, S. Schaefer, E. Rahimian, J. Baumgarten, C. R. Ball, M. Bornhaeuser, H. Glimm, M. Bill, A. A. Wurm
This study identifies KAT2A as a therapeutic target in a subset of well-differentiated, microsatellite-stable colorectal cancers by showing its dependency and functional consequences.
bioRxiv · Nov 15, 2023Cancer Biology